Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;172(1):118-126.
doi: 10.1016/j.surg.2022.02.005. Epub 2022 Mar 21.

Increasing rates of parathyroidectomy to treat secondary hyperparathyroidism in dialysis patients with Medicare coverage

Aarti Mathur  1 , JiYoon B Ahn  2 , Whitney Sutton  3 , Martha A Zeiger  4 , Dorry L Segev  5 , Mara McAdams-DeMarco  6
Affiliations

Increasing rates of parathyroidectomy to treat secondary hyperparathyroidism in dialysis patients with Medicare coverage

Aarti Mathur et al. Surgery. 2022 Jul.

Erratum in

Abstract

Background: Secondary hyperparathyroidism affects nearly all patients with renal failure on dialysis. Medical treatment of secondary hyperparathyroidism has considerably evolved over the past 2 decades, with parathyroidectomy reserved for severe cases. The primary objective of our study was to understand how trends in medical treatments affected parathyroidectomy rates in patients with secondary hyperparathyroidism on dialysis.

Methods: We used the United States Renal Data System to identify 379,835 adult patients (age ≥18) who were on maintenance dialysis in the United States between 2006 and 2016 with Medicare as the primary payor and ascertained treatment for secondary hyperparathyroidism. Adjusted rate ratios for rates of parathyroidectomy were calculated using multivariable-adjusted Poisson regression.

Results: Of 379,835 secondary hyperparathyroidism patients, 4,118 (1.1%) underwent parathyroidectomy, 39,835 (10.5%) received cinacalcet, 243,522 (64.1%) received phosphate binders, 17,571 (4.6%) received vitamin D analogs, and 86,899 (22.9%) received no treatment during the 10 years of follow-up. Over the entire study period, there was a 3.5-fold increase in the use of calcimimetics and a 3.4-fold increase in rates of parathyroidectomy. Compared to 2006 through 2009, utilization of parathyroidectomy increased 52% (adjusted rate ratio = 1.52, 95% confidence interval: 1.39-1.65) between 2010 and 2013 and by 106% (adjusted rate ratio = 2.06, 95% confidence interval: 1.90-2.24) between 2014 and 2016. The greatest increase in parathyroidectomy utilization occurred in younger patients (age 18-64 years), Black patients, female patients, those living in higher poverty neighborhoods, those listed for kidney transplant, and those who live in the Southern region of the United States.

Conclusion: Despite the evolution of medical treatments and an increase in the use of calcimimetics to treat secondary hyperparathyroidism, parathyroidectomy rates have been steadily increasing among dialysis patients with Medicare coverage.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest/Disclosures

The authors’ have no conflicts of interest to declare.

Figures

Figure 1.
Figure 1.
Overlap of treatments for secondary hyperparathyroidism (SHPT) among patients who initiated dialysis between 2004–2016 (n=379,835). Of those, 86,899 (22.9%) received no treatment. Treatments include: Parathyroidectomy (PTDx), Phosphate Binders, Vitamin D analogs, and Cinacalcet.
Figure 2.
Figure 2.. Trends of (a) parathyroidectomy, (b) cinacalcet, (c) phosphate binders, and (d) vitamin D among patients on dialysis in 2006–2016 (n=379,835).
In 2016, 9.8 parathyroidectomies were performed per 10,000 person-years and 652 patients received at least one cinacalcet prescription per 10,000 person-years. Patients who received parathyroidectomy were censored at the date of operation. Rates per 10,000 person-year and 95% confidence interval are presented for parathyroidectomy and 95% confidence intervals for medications are narrow to be presented.
Figure 2.
Figure 2.. Trends of (a) parathyroidectomy, (b) cinacalcet, (c) phosphate binders, and (d) vitamin D among patients on dialysis in 2006–2016 (n=379,835).
In 2016, 9.8 parathyroidectomies were performed per 10,000 person-years and 652 patients received at least one cinacalcet prescription per 10,000 person-years. Patients who received parathyroidectomy were censored at the date of operation. Rates per 10,000 person-year and 95% confidence interval are presented for parathyroidectomy and 95% confidence intervals for medications are narrow to be presented.
Figure 2.
Figure 2.. Trends of (a) parathyroidectomy, (b) cinacalcet, (c) phosphate binders, and (d) vitamin D among patients on dialysis in 2006–2016 (n=379,835).
In 2016, 9.8 parathyroidectomies were performed per 10,000 person-years and 652 patients received at least one cinacalcet prescription per 10,000 person-years. Patients who received parathyroidectomy were censored at the date of operation. Rates per 10,000 person-year and 95% confidence interval are presented for parathyroidectomy and 95% confidence intervals for medications are narrow to be presented.
Figure 2.
Figure 2.. Trends of (a) parathyroidectomy, (b) cinacalcet, (c) phosphate binders, and (d) vitamin D among patients on dialysis in 2006–2016 (n=379,835).
In 2016, 9.8 parathyroidectomies were performed per 10,000 person-years and 652 patients received at least one cinacalcet prescription per 10,000 person-years. Patients who received parathyroidectomy were censored at the date of operation. Rates per 10,000 person-year and 95% confidence interval are presented for parathyroidectomy and 95% confidence intervals for medications are narrow to be presented.
Figure 3.
Figure 3.. Trends of parathyroidectomy by (a) age, (b) sex, (c) race, (d) neighborhood poverty level, (e) being listed, and (f) region (Northeast, South, Midwest, and West).
Rates per 10,000 person-year and 95% confidence interval are presented. Listing status was assessed at each follow up time period.
See this image and copyright information in PMC

References

    1. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB 2017. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int 92:26–36. - PubMed
    1. Lau WL, Obi Y, Kalantar-Zadeh K 2018. Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol 13:952–961. - PMC - PubMed
    1. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD 2006. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70:771–780. - PubMed
    1. Kim SM, Long J, Montez-Rath ME, Leonard MB, Norton JA, Chertow GM 2016. Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States. Clin J Am Soc Nephrol 11:1260–1267. - PMC - PubMed
    1. Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS 2012. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494. - PubMed

Publication types